Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.

Background: There is a misconception that elderly cancer patients cannot tolerate standard doses of chemotherapy because of the frequency and severity of myelosuppressive complications. The reactive use of colony-stimulating factors (i.e.